How Much Does Mounjaro Cost in Vermont in 2026?

Mounjaro's List Price and What Vermont Patients Actually Pay

The sticker price for Mounjaro is $1,023 per month across all six dose strengths, set by Eli Lilly and consistent nationwide [1]. That figure reflects the wholesale acquisition cost (WAC) before any discounts, rebates, or insurance adjustments. Few Vermonters pay this amount out of pocket.

Actual cost depends on three variables: insurance status, diagnosis, and willingness to explore alternatives like compounded tirzepatide. A commercially insured patient with a type 2 diabetes diagnosis and an approved prior authorization might pay a copay between $25 and $150 per month. Uninsured patients filling at a Vermont retail pharmacy face the full $1,023.

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46% versus 1.86% with semaglutide 1 mg at 40 weeks [2]. That clinical performance makes tirzepatide one of the most effective glucose-lowering agents on the market, which is partly why payers have been willing to cover it despite the price. The SURMOUNT-1 trial (N=2,539) showed 22.5% mean body weight reduction with tirzepatide 15 mg versus 2.4% with placebo at 72 weeks [3]. These dual benefits make the cost conversation more complex than a simple price tag.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, noted in 2023: "The pricing of newer diabetes medications continues to be a barrier for many patients, and we need systemic solutions that go beyond manufacturer coupons" [4]. That observation holds true in Vermont, where affordability depends heavily on which cost-reduction pathway a patient can access.

Vermont Medicaid Coverage for Mounjaro

Vermont Medicaid covers Mounjaro with prior authorization for type 2 diabetes. The PA process typically requires documentation that the patient has tried and failed metformin, or has a clinical contraindication to first-line therapy. Processing takes 3 to 5 business days in most cases.

Off-label coverage for weight management through Vermont Medicaid is not standard. The program does not currently list tirzepatide as a preferred agent for obesity without a concurrent type 2 diabetes diagnosis. Patients seeking weight-loss coverage through Medicaid may need to appeal, and approval rates for off-label obesity use remain low across state Medicaid programs nationally.

Vermont's Medicaid program covers approximately 180,000 residents [5]. For those enrollees with type 2 diabetes, Mounjaro sits on the non-preferred tier, meaning the PA requirement adds an administrative step that metformin or sulfonylureas do not carry. The prescribing clinician must submit clinical justification, including HbA1c values, BMI, and a record of prior medication trials.

The Endocrine Society's 2022 Clinical Practice Guideline on pharmacological management of obesity recommends GLP-1 receptor agonists and GIP/GLP-1 dual agonists as second-line pharmacotherapy when lifestyle modification alone is insufficient [6]. Vermont Medicaid has not yet aligned its formulary with this recommendation for tirzepatide specifically, though coverage policies are reviewed annually.

Commercial Insurance Coverage in Vermont

Most major commercial insurers operating in Vermont cover Mounjaro for type 2 diabetes. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna all include tirzepatide on their formularies, though tier placement and PA requirements vary by plan.

Prior authorization is nearly universal. Insurers want to confirm the diagnosis is type 2 diabetes and that the patient meets clinical criteria. Some plans also require a step-through protocol where the patient tries a GLP-1 receptor agonist (such as semaglutide or liraglutide) before approving tirzepatide.

Coverage for obesity (off-label Mounjaro or branded Zepbound) is less predictable. Employer-sponsored plans in Vermont increasingly cover anti-obesity medications, but individual and small-group market plans lag behind. A 2024 analysis published in JAMA found that only 27% of marketplace plans covered any GLP-1-based anti-obesity medication [7]. Vermont's marketplace follows a similar pattern.

Copays under commercial insurance range from $25 to $150 per month for preferred-tier placement. Non-preferred tier placement can push copays to $200 to $350, making the Eli Lilly Savings Card an important cost-reduction tool.

The Eli Lilly Savings Card: How It Works in Vermont

Eli Lilly offers a manufacturer savings card that reduces out-of-pocket costs for commercially insured patients to as little as $25 per monthly fill. The card is not available to patients with government insurance, including Medicaid, Medicare, or Tricare.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Mounjaro, a valid prescription, and must not be enrolled in any federal or state government healthcare program. The card covers the difference between the patient's copay and $25, up to a maximum annual benefit (currently $150 per fill, capped at $1,800 per calendar year).

Vermont patients can activate the card at lilly.com or by calling 1-800-545-6962. The card works at all major Vermont retail pharmacies, including CVS, Walgreens, Kinney Drugs, and independent pharmacies. Processing is handled at the point of sale through the pharmacy's adjudication system.

One critical detail: the savings card applies only when the patient's insurance covers Mounjaro. If the prior authorization is denied or the plan excludes tirzepatide, the card cannot be used. Patients who receive a PA denial should work with their prescriber to file an appeal before assuming they must pay cash price.

Compounded Tirzepatide in Vermont: Legality, Cost, and Risks

Compounded tirzepatide is available in Vermont through licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% cost reduction compared to the branded product.

The legal framework is clear. Under federal law, 503A pharmacies may compound tirzepatide pursuant to a valid patient-specific prescription when a prescriber determines that a compounded preparation is medically appropriate. The FDA's position on compounding has shifted over time, particularly after tirzepatide was removed from the drug shortage list in October 2024, which triggered enforcement actions against some compounders nationally [8].

Vermont follows the standard 503A regulatory framework. The Vermont Board of Pharmacy licenses compounding pharmacies and conducts inspections. Patients receiving compounded tirzepatide should verify that their pharmacy holds a current Vermont compounding license and sources tirzepatide base from an FDA-registered supplier.

Quality is the primary concern. Branded Mounjaro undergoes rigorous lot testing and FDA-mandated quality controls. Compounded versions do not carry FDA approval, and potency, sterility, and endotoxin testing standards vary by pharmacy. The FDA issued a safety communication in 2024 warning that some compounded semaglutide and tirzepatide products contained salt forms not equivalent to the approved drugs [9].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "Patients considering compounded GLP-1 receptor agonists should understand that these are not FDA-approved products, and the quality controls differ substantially from manufactured medications" [10]. Vermont patients choosing this route should ask their compounding pharmacy for certificates of analysis and verify the specific salt form being dispensed.

Telehealth Access to Mounjaro in Vermont

Vermont permits telehealth prescribing of Mounjaro. Patients can consult with licensed prescribers via video or audio visits and receive a prescription that can be filled at any Vermont pharmacy or through mail-order services.

Several national telehealth platforms operate in Vermont and prescribe tirzepatide, including Hims & Hers, Ro, and Found. These platforms typically charge a consultation fee ($49 to $149 per visit) in addition to the medication cost. Some bundle the consultation with compounded tirzepatide at a single monthly rate.

Vermont's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person visits, which means the prescribing consultation itself may be covered by insurance even if the patient pays out of pocket for the medication. This law was extended beyond its pandemic-era provisions and is now permanent.

For patients in rural Vermont counties (Essex, Orleans, Caledonia), telehealth removes a significant access barrier. The nearest endocrinologist or obesity medicine specialist may be 60 to 90 minutes away. A telehealth consultation followed by mail-order pharmacy delivery makes tirzepatide accessible regardless of geography.

Comparing Cost-Reduction Strategies for Vermont Patients

Six pathways can lower the out-of-pocket burden for Mounjaro in Vermont. Each comes with tradeoffs.

Commercial insurance with the Lilly Savings Card produces the lowest reliable cost: $25 per month for eligible patients. This requires an approved PA, commercial coverage, and no government insurance enrollment.

Compounded tirzepatide through a 503A pharmacy runs approximately $249 per month. It avoids insurance entirely but carries quality variability and regulatory uncertainty.

Manufacturer patient assistance programs from Eli Lilly provide free Mounjaro to uninsured patients with household incomes below 400% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $62,400 [1].

GoodRx and similar discount cards offer minimal savings on Mounjaro. Cash-price discount cards typically reduce the cost by $50 to $100 off the $1,023 list price, which is not enough to make the medication affordable for most uninsured patients.

Switching to Zepbound may help patients whose primary indication is weight management rather than diabetes. Zepbound (also tirzepatide, also made by Eli Lilly) has its own savings card program and may be on a different formulary tier depending on the insurer [1].

Mail-order pharmacy can reduce per-fill costs by 5% to 15% compared to retail, depending on the pharmacy benefit manager. Express Scripts, OptumRx, and CVS Caremark all offer mail-order fulfillment for Mounjaro in Vermont.

Mounjaro Dosing, Titration, and How It Affects Total Cost

Mounjaro uses a fixed titration schedule regardless of price tier. All patients start at 2.5 mg weekly for four weeks, then increase to 5 mg [1]. The prescriber may increase the dose by 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly.

Each dose level costs the same at list price. One KwikPen containing four weekly doses costs $1,023 whether it delivers 2.5 mg or 15 mg. This flat pricing structure means that cost does not change as patients titrate upward.

Total annual cost at list price is $12,276. With the Lilly Savings Card, annual out-of-pocket drops to $300 (at $25 per fill). With compounded tirzepatide, annual cost is approximately $2,988.

Treatment duration matters for total expenditure. SURMOUNT-4 demonstrated that patients who discontinued tirzepatide after 36 weeks regained approximately 14% of lost body weight over the subsequent 52 weeks, while those who continued lost an additional 5.5% [11]. This finding suggests that tirzepatide for weight management is a long-term commitment, not a short course. Vermont patients should factor ongoing annual costs into their decision.

The SURPASS-2 trial showed that at the 5 mg dose, tirzepatide reduced HbA1c by 2.01% and body weight by 7.6 kg at 40 weeks [2]. Even at the starting therapeutic dose, the clinical benefit is substantial. Not every patient needs to titrate to 15 mg, and some clinicians in Vermont keep patients at 5 mg or 7.5 mg if glycemic and weight targets are met. Staying at a lower dose does not save money on branded Mounjaro (same price per pen), but it can reduce the dose needed in compounded formulations, potentially lowering compounded cost below $249.

What to Do If Your Insurance Denies Mounjaro in Vermont

PA denials are common and not final. The first step is to request the specific denial reason from the insurer. Common reasons include: incomplete documentation, failure to demonstrate prior medication trials, or an off-label indication.

Vermont insurance regulations give patients the right to an internal appeal within 30 days and, if the internal appeal fails, an external review through the Vermont Department of Financial Regulation. External reviews are decided by an independent review organization (IRO), and the IRO's decision is binding on the insurer.

Prescribers can improve approval odds by submitting a comprehensive letter of medical necessity that includes the patient's HbA1c history, BMI, comorbidity list, and a record of all prior diabetes or weight-management medications tried. Including citations to SURPASS or SURMOUNT trial data in the letter can strengthen the clinical argument for tirzepatide over alternative agents.

The appeal process takes 30 to 60 days for standard cases. Vermont law requires expedited review within 72 hours when the prescriber certifies that a delay would seriously jeopardize the patient's health [12].